Company Participants expansions? I know the second-line Phase 3 trial, I believe, is fully enrolled now. And you also started the firstline DLBCL trial recently. Just curious sort of how we should think about the pace of possible label expansions into larger markets. And then a follow-up. Your competitor, Roche, is marketing sort of this fixed duration treatment aggressively for their CD20 bispecific antibodies. Just curious if that is something that is under consideration for EPKINLY as well or if you're s ...

Exhibit 99.1 Genmab Announces Financial Results for the First Half of 2023 August 3, 2023 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2023 Highlights "The U.S. FDA approval of EPKINLY as the first bispecific antibody to treat adults with relapsed or refractory DLBCL was an important milestone both for Genmab and for patients in need of an innovative treatment option administered subcutaneously. We would like to thank the patients and investigators who took part in the EPCORE ...

Company Participants Before we look at our first quarter results, I want to remind you of our consistent track record of success. Our proprietary technologies fuel our robust product engine, which is both expanding and maturing. By the end of this year, there is the potential for 8 approved medicines powered by our innovation, half of which would be DuoBody-based bispecifics. This is validation of the DuoBody technology's potential to create truly differentiated bispecific antibody therapeutics, and our gro ...

Exhibit 99.1 Genmab Announces Financial Results for the First Quarter of 2023 May 10, 2023 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2023 Highlights ● Genmab revenue increased 35% compared to the first quarter of 2022, to DKK 2,854 million "In the first quarter of the year we continued to lay the groundwork for the potential approval of epcoritamab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Looking beyond this indication, together with our partner AbbVie In ...

And the first question on the data in relapsed refractory lymphoma and also follicular lymphoma, I will ask Judith to give you a bit more color on timing. Judith. Thank you. And your next question comes from the line of Michael Schmidt from Guggenheim. Please go ahead, your line is open. Thanks, Paul. I will hand over the question to Taham, and then the perhaps Judith can also chip in I think after Taham has already given his initial thoughts on the B7-H4 bispecific program, which we are very excited about. ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ◻ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ◻ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 1 ...

Exhibit 99.1 GENMAB 2022 ANNUAL REPORT Table of Contents | MANAGEMENT'S REVIEW | | | --- | --- | | Our Vision | 2 | | Chair's Statement | 2 | | Letter from the CEO | 3 | | 2022 at a Glance | 4 | | Consolidated Key Figures | 6 | | 2023 Outlook | 9 | | Our Strategy | 11 | | Who We Are | 13 | | Business Model | 14 | | Research and Development Capabilities | 15 | | Enhancing Commercialization Capabilities to Bring Our Innovations to Patients | 16 | | Antibody Discovery and Development | 17 | | Products and Tech ...

Quarter End Results Period Ended September 30, 2022 Forward looking statement This presentation contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including develop ...

Genmab A/S (GMAB) Q3 2022 Earnings Conference Call November 9, 2022 12:00 PM ET Company Participants Jan van de Winkel – Chief Executive Officer Anthony Pagano – Chief Financial Officer Tahi Ahmadi – Chief Medical Officer Conference Call Participants Wimal Kapadia – Bernstein Jonathan Chang – SVB Securities Peter Verdult – Citi Paul Jeng – Guggenheim Partners Peter Welford – Jefferies Emily Field – Barclays Elizabeth Walton – Credit Suisse Michael Novod – Nordea Asthika Goonewardene – Truist Securities Zoe ...

Genmab A/S (GMAB) Q2 2022 Results Conference Call August 10, 2022 12:00 PM ET Company Participants Jan van de Winkel - President and CEO Anthony Pagano - CFO Judith Klimovsky - Chief Development Officer Anthony Mancini - COO Tahi Ahmadi - Chief Medical Officer Conference Call Participants Wimal Kapadia - Bernstein Jonathan Chang - SVB Sachin Jain - Bank of America Asthika Goonewardene - Truist Securities James Gordon - JP Morgan Paul Jeng - Guggenheim Securities Elizabeth Walton - Credit Suisse Zoe Karamano ...